1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €26.76 (+124.87%). The median is €26.76 (+124.87%).
| Buy |
3 |
| Hold |
0 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -10.28M | 19.74% |
| EBITDA | -10.28M | 19.74% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €15.79M |
Number of shares | 1.31M |
52-week high/low | €23.65 - €5.41 |
| Dividends | No |
Beta | -0.22 |
P/E ratio | -0.83 |
PEG ratio | 0.00 |
P/B ratio | 2.59 |
P/S ratio | 0.00 |
Company profile
| Name | ProMIS Neurosciences |
| CEO | Neil K. Warma |
| Employees | 11 |
Discover assets
Shareholders of ProMIS Neurosciences also invest in the following assets
